1. Home
  2. KIO vs REPL Comparison

KIO vs REPL Comparison

Compare KIO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KIO
  • REPL
  • Stock Information
  • Founded
  • KIO 2011
  • REPL 2015
  • Country
  • KIO United States
  • REPL United States
  • Employees
  • KIO 2400
  • REPL N/A
  • Industry
  • KIO Investment Managers
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • KIO Finance
  • REPL Health Care
  • Exchange
  • KIO Nasdaq
  • REPL Nasdaq
  • Market Cap
  • KIO 522.7M
  • REPL 547.0M
  • IPO Year
  • KIO N/A
  • REPL 2018
  • Fundamental
  • Price
  • KIO $12.46
  • REPL $4.65
  • Analyst Decision
  • KIO
  • REPL Hold
  • Analyst Count
  • KIO 0
  • REPL 9
  • Target Price
  • KIO N/A
  • REPL $6.67
  • AVG Volume (30 Days)
  • KIO 136.5K
  • REPL 4.7M
  • Earning Date
  • KIO 01-01-0001
  • REPL 11-11-2025
  • Dividend Yield
  • KIO 10.82%
  • REPL N/A
  • EPS Growth
  • KIO N/A
  • REPL N/A
  • EPS
  • KIO N/A
  • REPL N/A
  • Revenue
  • KIO N/A
  • REPL N/A
  • Revenue This Year
  • KIO N/A
  • REPL N/A
  • Revenue Next Year
  • KIO N/A
  • REPL N/A
  • P/E Ratio
  • KIO N/A
  • REPL N/A
  • Revenue Growth
  • KIO N/A
  • REPL N/A
  • 52 Week Low
  • KIO $10.52
  • REPL $2.68
  • 52 Week High
  • KIO $13.59
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • KIO 44.48
  • REPL 47.54
  • Support Level
  • KIO $12.29
  • REPL $4.57
  • Resistance Level
  • KIO $12.52
  • REPL $4.46
  • Average True Range (ATR)
  • KIO 0.11
  • REPL 0.32
  • MACD
  • KIO -0.03
  • REPL 0.12
  • Stochastic Oscillator
  • KIO 38.30
  • REPL 92.36

About KIO KKR Income Opportunities Fund

KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: